Abstract

OBJECTIVE To evaluate the effect of gonadotropin-releasing hormone (GnRH) agonist, administered in the luteal phase, on intracytoplasmic sperm injection (ICSI) outcome. MATERIALS AND METHODS One hundred and eighty women undergoing ovarian stimulation for ICSI were enrolled in this study. Patients were randomly assigned to receive a single dose of GnRH agonist or placebo. Implantation rate and clinical pregnancy rate were the main outcomes. RESULTS Administration of 0.1 mg of the GnRH agonist triptorelin on day 3 after embryo transfer led to a significant improvement in implantation rate (12.3% vs. 7.3%) and clinical pregnancy rate (25.5% vs. 10.0%) as compared with placebo. CONCLUSION Luteal phase GnRH agonist administration enhances ICSI clinical outcomes.